Beam Therapeutics Inc. (BEAM)
Nasdaq · Healthcare · Biotechnology
$25.67+4.78%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.7B
- 52-week range
- $20.23 – $38.26
- 52-week change
- −2.51%
- EPS (trailing)
- −$0.68
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $140M (+120.00%)
- Net income
- −$80.0M
- Operating margin
- −274.6%
- Diluted EPS
- −$0.81
- Free cash flow
- −$360M
From the company’s annual report on SEC EDGAR.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE.
Headquarters: Cambridge, United States · 540 employees · beamtx.com